Title: A multi-omics approach for type 2 diabetes target discovery: identification and characterisation of disease-specific small open reading frame encoded peptides

Company: Novo Nordisk

Presenter: Dr. Bill Haynes, Site Head and Vice President, Novo Nordisk Research Centre Oxford.

Bio: Bill is a physician-scientist with more than 25 years of experience in academic-industry translational research across diabetes and cardiometabolic diseases. Following a successful career as a physician, and 10 years as Professor of Cardiovascular Medicine and Endocrinology (University of Iowa, US), Bill went on to lead multidisciplinary discovery research groups at Novartis and AstraZeneca. Bill joined Novo Nordisk Research Centre Oxford (NNRCO) in December 2018 to help drive the identification and validation of novel targets for Type 2 diabetes and cardiometabolic diseases. NNRCO employs advanced bioinformatics, state-of-the-art discovery screening technologies and human centric systems, taking advantage of academic-industrial collaborations, human genetics and big data to conduct world-class discovery and translational research.

Lunch will be provided and the seminar will be followed by networking.

If you would prefer not to use eventbrite from a GDPR perspective then please email Siobhan.Dennis@Medsci.ox.ac.uk to register.